Dr. Patrick B. Wood is a respected authority on the cause and treatment of Fibromyalgia Syndrome who has been twice recognized by the National Institutes for Health for his innovative research. He is a nationally-known speaker on the subject of Fibromyalgia and has presented his work at scientific conferences around the world.

Dr. Wood's professional responsibilities include appointments as Assistant Professor in the Departments of Family Medicine, Psychiatry and Anesthesiology at Louisiana State University Health Sciences Center in Shreveport, where he directs both the Fibromyalgia Research Program and the Fibromyalgia Care Clinic. He has been a Visiting Scholar at the world-renowned Centre for Research on Pain at McGill University in Montreal, Canada. Dr. Wood also serves as chief medical advisor for Angler Biomedical Technologies, LLC.

In addition, Dr. Wood is the originator of the Dopamine Theory of Fibromyalgia and has spearheaded the use of advanced imaging technologies including Positron Emission Tomography and Magnetic Resonance Spectroscopy to investigate fundamental changes within the central nervous system that result in the development of Fibromyalgia.

Bibliography:

Publications:

• Wood PB. Fibromyalgia. Elsevier Encyclopedia of Stress, Second Edition. 2007 (In Press)
• Wood PB, Patterson JC II, Sunderland JJ, Tainter KH, Glabus MF, Lilien DL. Reduced presynaptic dopamine activity in Fibromyalgia Syndrome demonstrated with PET: A pilot study. J Pain. 2006 (in press)
• Wood PB, Patterson JC II, Jasmin LD. Insular Hypometabolism in a Patient with Fibromyalgia: A Case Study. Pain Medicine, 2006 (In Press)
• Wood PB. A reconsideration of the relevance of systemic, low-dose ketamine to the pathophysiology of fibromyalgia. J Pain. 2006 (in press)
• Wood PB. Mesolimbic dopaminergic mechanisms and pain control. Pain. 2006; 120:230-234.
• Wood PB. Neuroimaging in Functional Somatic Syndromes. International Review of Neurobiology. 2005;67:119-163.
• Wood PB, Kablinger AS, Caldito GS. Open trial of pindolol in the treatment of fibromyalgia. Annals of Pharmacotherapy. 2005 Nov;39(11):1812-1816.
• Cork RC, Wood PB, Ming N, Shepherd C, Eddy J, Price L. The Effect of Cranial Electrotherapy Stimulation (CES) on Pain Associated with Fibromyalgia. The Internet Journal of Anesthesiology. 2004. 8(2)
• Wood PB. Stress and dopamine: implications for the pathophysiology of chronic widespread pain. Medical Hypotheses. 2004;62(3):420-4.
• Wood PB. Fibromyalgia: A Central Role for the Hippocampus - A Theoretical Construct. J Musculoskeletal Pain 2004;12(1):19-26

ˆ Back to Bibliography

Abstracts:

• Simpson R, Glabus MF, Patterson JC II, Wood PB. Is reduced dopamine availability the catalyst for grey matter changes in fibromyalgia syndrome? Society for Neuroscience. Neuroscience 2006. Atlanta, GA. October, 2006
• Wood PB, Bushnell MC, Dagher A, Jaeger E, Haykemez H, Rabiner EA, Chizh BA. Disruption of Dopaminergic Reactivity in Fibromyalgia Demonstrated by 11C-raclopride/PET. European Federation of IASP Chapters (EFIC), Pain in Europe V. Istanbul, Turkey. September, 2006.
• Wood PB, Jaeger E, Hakyemez H, Dagher A, Bushnell MC, Rabiner EA, Chizh BA. The Role of Striatal Dopamine in Response to a Tonic Pain Stimulus: a PET Study Using 11C-Raclopride. Organization for Human Brain Mapping, 12th Annual Meeting. Florence, Italy. July 2006.
• Kuchinad A, Wood PB, Lyttelton O, Chizh BA, Bushnell MC. Reductions in Cortical Grey Matter Density Associated with Fibromyalgia Syndrome. Organization for Human Brain Mapping, 12th Annual Meeting. Florence, Italy. July 2006.
• Wood PB, Jaeger E, Bushnell MC, Rabiner EA, Chizh BA. Hyperalgesia and adaptation to a tonic pain stimulus in fibromyalgia patients and controls. The American Pain Society's 25th Annual Scientific Meeting. San Antonio, TX. May 2006.
• Wood PB. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial Comparing the Effects of Orally Administered Xyrem® (Sodium Oxybate) with Placebo for the Treatment of Fibromyalgia. American Academy of Pain Medicine, 22nd Annual Meeting. San Diego, CA. February 2006.
• Wood PB. Stress-enhanced Hippocampal Throughput and Tonic/Phasic Dopamine: Implications for Fibromyalgia Syndrome. International Association for the Study of Pain, 11th World Congress on Pain. Sydney, Australia. September 2005.
• Patterson JC II, Tainter K, Glabus MF, Sunderland J, Lillien D, Wood PB. Reduced presynaptic dopamine in fibromyalgia. Organization for Human Brain Mapping, 11th Annual Meeting. Toronto, Canada. June 2005.
• Wood PB. Stress-enhanced Hippocampal Throughput and Meso-limbic Dopamine: Implications for Fibromyalgia. Oregon Health Sciences University/National Institutes of Health. Fibromyalgia Workshop: The Next Advances. Washington, DC. November 2004. (Awarded New Investigator, National Institutes for Health)
• Wood PB, Hill AL, Glabus MF, Patterson JP. Hippocampal Metabolite Abnormalities in Fibromyalgia and their Symptom Correlates. International Myopain Society. Sixth World Congress on Myofascial Pain and Fibromyalgia, Munich, Germany July 2004.
• Glabus MF, Hill AL, Featherston L, Wood PB. Brain Structural Abnormalities and their Symptom Correlates in Fibromyalgia Syndrome. Organization for Human Brain Mapping, Budapest, Hungary, June 2004
• Wood PB, Kablinger AS, Freeman, AM 3rd. An Open Label Trial of the Efficacy of Pindolol in the Treatment of Fibromyalgia. NIMH/NCDEU 42nd Annual Meeting. Poster III-67 (Awarded NIMH New Clinical Investigator)
• Wood PB. Fibromyalgia: A Central Role for the Hippocampus. LSU Health Sciences Center Neuroscience Research Day 2003.